Review
Current status of selegiline as a neuroprotective agent in Parkinson's disease
Affiliations
- PMID: 9613720
Item in Clipboard
Review
Current status of selegiline as a neuroprotective agent in Parkinson's disease
Mov Disord.
1998.
No abstract available
Similar articles
-
Moderate Parkinson's disease. Strategies for maximizing treatment.Postgrad Med. 1996 Jan;99(1):52-4, 61-3, 67-8, passim. Postgrad Med. 1996. PMID: 8539210 Review.
-
[Drug therapy of Parkinson's disease].Duodecim. 1997;113(18):1827-34. Duodecim. 1997. PMID: 10892076 Review. Finnish. No abstract available.
-
Selegiline in Parkinson's disease.BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583. BMJ. 1995. PMID: 8555790 Free PMC article. No abstract available.
-
Deprenyl in Parkinson's disease.Ann Neurol. 1996 Aug;40(2):268-9. doi: 10.1002/ana.410400229. Ann Neurol. 1996. PMID: 8773617 No abstract available.
-
Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.Neurology. 2001 Jul 24;57(2):369; author reply 369-70. Neurology. 2001. PMID: 11480425 No abstract available.
Cited by
-
Neuroprotection in Parkinson's disease; a commentary.Neurotox Res. 2002 Mar;4(2):141-5. doi: 10.1080/10298420290015881. Neurotox Res. 2002. PMID: 12829414
-
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003. Clin Pharmacokinet. 2002. PMID: 11978145 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical